Clinical Trials
81 trialsTesting the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma
NRG Oncology
MYSTIC
AstraZeneca
Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC
Innovent Biologics (Suzhou) Co. Ltd.
PAPILLON
Janssen Research & Development, LLC
MARIPOSA-2
Janssen Research & Development, LLC
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer
Hoffmann-La Roche
NEPTUNE
AstraZeneca
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
Hoffmann-La Roche
POD1UM-304
Incyte Corporation
POSEIDON
AstraZeneca
Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)
AstraZeneca
AcceleRET-Lung
Hoffmann-La Roche
CANOPY-1
Novartis
Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)
Merck Sharp & Dohme LLC
innovaTV 301
Seagen Inc.
LEAP-006
Merck Sharp & Dohme LLC
MK-7684A-007
Merck Sharp & Dohme LLC
CheckMate 816
Bristol-Myers Squibb
CheckMate 9LA
Bristol-Myers Squibb
MK-3475A-D77
Merck Sharp & Dohme LLC
CheckMate 227
Bristol-Myers Squibb
Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer
AstraZeneca
LIBRETTO-431
Eli Lilly and Company
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
Bristol-Myers Squibb
FLAURA2
AstraZeneca
MK-3475A-D77
Merck Sharp & Dohme LLC
LEAP-006
Merck Sharp & Dohme LLC
CONTERNO
Checkpoint Therapeutics, Inc.
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery
National Cancer Institute (NCI)
LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib
Novartis
A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer
BeiGene
Avelumab in First-line NSCLC (JAVELIN Lung 100)
EMD Serono
LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer
Novartis
ZEAL
Sanofi
MK-3475-671
Merck Sharp & Dohme LLC
MK-3475-A86
Merck Sharp & Dohme LLC
MK-3475-789
Merck Sharp & Dohme LLC
MK-3475-189
Merck Sharp & Dohme LLC
MK-3475-189
Merck Sharp & Dohme LLC
CheckMate743
Bristol-Myers Squibb
Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer
EQRx International, Inc.
GEOMETRY-E
Novartis
ATALANTE-1
OSE Immunotherapeutics
A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)
Hoffmann-La Roche
Keynote 042
Merck Sharp & Dohme LLC
CheckMate722
Bristol-Myers Squibb
Keynote 042
Merck Sharp & Dohme LLC
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer
Eisai Inc.
A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]
Hoffmann-La Roche
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
Bristol-Myers Squibb